Abstract
Purpose
A clinically relevant animal model for cancer of the esophagogastric junction does not exist. This study aimed to establish an orthotopic mouse model for human gastric cancer of the distal stomach and the gastric cardia.
Materials and methods
Human gastric cancer cell lines AGS, MKN-45, and NCI-N87 were injected subcutaneously into nude mice. These donor tumors were harvested after 4 weeks and minced into small tumor fragments. One donor tumor fragment was orthotopically implanted into the submucosa of either gastric cardia or distal stomach in other mice. The animals were killed 4, 8, and 12 weeks after tumor implantation. Volume of the primary tumor and local and systemic tumor spread were determined.
Results
The implantation technique resulted in a tumor take rate of 100%. An artificial dissemination of tumor cells into the abdominal cavity due to the procedure was not observed.
Conclusions
We report for the first time the development of a clinically relevant mouse model for human gastric cancer of the gastric cardia and the distal stomach. Primary tumor growth and local and systemic spread progressed continuously during the observation period and mimic the human situation of this disease. This model may be suitable to evaluate novel treatment strategies for this malignancy.
Similar content being viewed by others
References
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43–66
Forman D, Burley VJ (2006) Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol 20:633–649
Li H, Yao SC (1997) Surgical treatment for carcinomas of the oesophagus in Chinese language publications. Br J Surg 84:855–857
Stein HJ, von Rahden BH, Hofler H, Siewert JR (2003) Karzinom des osophagogastralen Ubergangs und Barrett-Osophagus. Ein nahezu klares onkologisches Modell? Chirurg 74:703–708
Freedman ND, Abnet CC, Leitzmann MF, Mouw T, Subar AF, Hollenbeck AR, Schatzkin A (2007) A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am J Epidemiol 165:1424–1433
Pera M (2003) Trends in incidence and prevalence of specialized intestinal metaplasia, Barrett’s esophagus, and adenocarcinoma of the gastroesophageal junction. World J Surg 27:999–1008
Tajima Y, Yamazaki K, Makino R, Nishino N, Masuda Y, Aoki S, Kato M, Morohara K, Kusano M (2007) Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach. Br J Cancer 96:631–638
Böttcher KEM, Stein HJ, Roder JD, Siewert JR (1999) Chirurgische Therapie bei Karzinomen des proximalen Magendrittels und des ösophagogastralen Übergangs. Chir Gastroenterol 15:237–243
Siewert JRHAH, Becker K, Gössner W (1987) Cardia cancer: attempt at a therapeutically relevant classification. Chirurg 58:25–32
von Rahden BH, Feith M, Stein HJ (2005) Carcinoma of the cardia: classification as esophageal or gastric cancer? Int J Colorectal Dis 20:89–93
Ichikura T, Chochi K, Sugasawa H, Mochizuki H (2007) Proposal for a new definition of true cardia carcinoma. J Surg Oncol 95:561–566
Verdecchia ACI, Gatta G, Lisi D, Faivre J, Forman D, EUROCARE Working Group (2004) Explaining gastric cancer survival differences among European countries. Int J Cancer 109:737–741
Kim DY, Joo JK, Ryu SY, Park YK, Kim YJ, Kim SK (2006) Clinicopathological characteristics and prognosis of carcinoma of the gastric cardia. Dig Surg 23:313–318
Saito H, Fukumoto Y, Osaki T, Fukuda K, Tatebe S, Tsujitani S, Ikeguchi M (2006) Distinct recurrence pattern and outcome of adenocarcinoma of the gastric cardia in comparison with carcinoma of other regions of the stomach. World J Surg 30:1864–1869
Sutter AP, Zeitz M, Scherubl H (2004) Recent results in understanding molecular pathways in the medical treatment of esophageal and gastric cancer. Onkologie 27:17–21 (see comment)
Kretzschmar A, Schlag PM (2006) Efficacy of current adjuvant and neoadjuvant therapeutic concepts in gastric cancer? Zentralbl Chir 131:121–125
Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJH, Nicolson M, carffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20
Furukawa T, Fu X, Kubota T, Watanabe M, Kitajima M, Hoffman RM (1993) Nude mouse metastatic models of human stomach cancer constructed using orthotopic implantation of histologically intact tissue. Cancer Res 53:1204–1208
Hotz HG, Reber HA, Hotz B, Yu T, Foitzik T, Buhr HJ, Cortina G, Hines OJ (2003) An orthotopic nude mouse model for evaluating pathophysiology and therapy of pancreatic cancer. Pancreas 26:e89–e98
McColl KE (2006) Cancer of the gastric cardia. Best Pract Res Clin Gastroenterol 20:687–696
Cronin-Fenton DP, Sharp L, Carsin AE, Comber H (2007) Patterns of care and effects on mortality for cancers of the oesophagus and gastric cardia: a population-based study. Eur J Cancer 43:565–575
Valverde CM, Macarulla T, Casado E, Ramos FJ, Martinelli E, Tabernero J (2006) Novel targets in gastric and esophageal cancer. Crit Rev Oncol /hematol 59:128–138
Tabernero J, Macarulla T, Ramos FJ, Baselga J (2005) Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann Oncol 16:1740–1748
Saikawa Y, Kubota T, Kuo TH, Tanino H, Kase S, Furukawa T, Watanabe M, Ishibiki K, Kitajima M, Hoffman RM (1994) Combined effect of 5-fluorouracil and carboplatin against human gastric cancer cell lines in vitro and in vivo. Anticancer Res 14:461–464
Recchia F, Saggio G, Candeloro G, Cesta A, Amiconi G, Blasio AD, Necozione S, Rea S (2007) Chemoimmunotherapy in the treatment of metastatic gastric cancer. Anti-Cancer Drugs 18:597–604
Liang DM, Chen JY, Zhang Y, Gan P, Lin J, Chen AB (2006) Effects of recombinant human growth hormone on growth of human gastric carcinoma xenograft model in nude mice. World J Gastroenterol 12:3810–3813
Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, Moriya Y, Mori K, Tanaka Y (2007) Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol 59:795–805
Koyama TTA, Nariai K, Mitsunaga M, Yanaga K, Takahashi H (2007) Novel biomedical imaging approach for detection of sentinel nodes in an experimental model of gastric cancer. Br J Surg 94:996–1001
Kerbel RS (2003) Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther 2:S134–S139
Onn A, Isobe T, Itasaka S, Wu W, O’Reilly MS, Ki Hong W, Fidler IJ, Herbst RS (2003) Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. Clin Cancer Res 9:5532–5539
Takahashi T, Morotomi M, Nomoto K (2004) A novel mouse model of rectal cancer established by orthotopic implantation of colon cancer cells. Cancer Sci 95:514–519
Hotz HG, Reber HA, Hotz B, Foitzik T, Buhr HJ, Cortina G, Hines OJ (2001) An improved clinical model of orthotopic pancreatic cancer in immunocompetent Lewis rats. Pancreas 22:113–121
Acknowledgments
We thank Sonja Dullat, Marco Arndt, and Petra Schwartz for their technical support.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bhargava, S., Hotz, B., Buhr, H.J. et al. An orthotopic nude mouse model for preclinical research of gastric cardia cancer. Int J Colorectal Dis 24, 31–39 (2009). https://doi.org/10.1007/s00384-008-0584-z
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00384-008-0584-z